Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Discover how this crimson brew may lower blood pressure as effectively as medication while offering additional heart health ...

Brazilian researchers discover traditional fermented drink kefir significantly improves memory and cognitive function in ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

U.S. President Donald Trump plans to nominate Susan Monarez as director of the Centers for Disease Control and Prevention, ...

Two UIC professors list their questions for the man set to lead "the crown jewel” of American biomedical science.